GlassScriptPhysician profile
Marissa Ceresnie
NPI 1417585068
$19,886.74
in general payments reported to CMS, 2019-2025
32 companies · $7,838 in 2025
The $7,838 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.99 · 2021: $391 · 2022: $363 · 2023: $2,040 · 2024: $9,232 · 2025: $7,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $2,633 · Travel and Lodging: $1,016 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,198.12 |
| Consulting Fee | $2,632.50 |
| Travel and Lodging | $1,016.23 |
| Education | $262.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,529.81 | 2021-2025 | Skyrizi, Rinvoq, Botox |
| Incyte Corporation | $2,400.35 | 2023-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $2,196.79 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $2,076.30 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,052.97 | 2024-2025 | |
| Lilly USA, LLC | $897.29 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Biotech, INC. | $852.26 | 2024-2025 | Tremfya |
| Almirall LLC | $793.72 | 2024-2025 | Klisyri, Seysara |
| Arcutis Biotherapeutics, INC. | $732.11 | 2023-2025 | Zoryve |
| Pfizer INC. | $637.09 | 2023-2025 | |
| Galderma Laboratories, L.P. | $574.54 | 2023-2025 | Nemluvio, Aklief |
| Ucb, INC. | $567.85 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $464.99 | 2023-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $453.15 | 2023-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.34 | 2023-2025 | Spevigo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $257.86 | 2023-2024 | Poteligeo |
| Amgen INC. | $223.99 | 2021-2024 | Otezla |
| Blueprint Medicines Corporation | $209.62 | 2025 | Ayvakit |
| Dermavant Sciences, INC. | $205.36 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $201.77 | 2021-2025 | Dupixent |
| Organon LLC | $199.35 | 2025 | Vtama |
| Merz North America, INC. | $193.82 | 2025 | |
| Sandoz INC. | $129.16 | 2024 | Hyrimoz |
| Genentech USA, INC. | $127.68 | 2022 | |
| Stemline Therapeutics INC. | $117.28 | 2021 | |
| Boston Scientific Corporation | $114.18 | 2021 | |
| Journey Medical Corporation | $111.59 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $58.44 | 2023 | |
| Biofrontera INC. | $22.37 | 2025 | |
| Chiesi USA, INC. | $21.99 | 2024 | Filsuvez |
| Helsinn Therapeutics (U.S.), INC. | $20.55 | 2025 | Valchlor |
| Botanix Sb INC | $18.17 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Ceresnie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.